Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
428.12M | 354.10M | 100.06M | 110.27M | 0.00 | Gross Profit |
415.92M | 317.22M | 97.48M | 93.07M | 0.00 | EBIT |
-618.10M | -434.80M | -295.38M | -3.88B | -804.70M | EBITDA |
-574.46M | -269.77M | -259.25M | -3.86B | -785.71M | Net Income Common Stockholders |
-515.24M | -359.36M | -308.12M | -3.90B | -832.73M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
2.16B | 2.72B | 3.18B | 3.52B | 354.08M | Total Assets |
3.77B | 3.88B | 3.93B | 3.93B | 529.95M | Total Debt |
753.24M | 418.71M | 121.97M | 39.26M | 66.86M | Net Debt |
334.82M | -432.32M | -482.10M | -1.48B | -132.54M | Total Liabilities |
1.29B | 896.11M | 593.10M | 289.07M | 1.62B | Stockholders Equity |
2.47B | 2.99B | 3.34B | 3.65B | -1.09B |
Cash Flow | Free Cash Flow | |||
0.00 | -686.23M | -681.48M | -387.50M | -139.26M | Operating Cash Flow |
0.00 | -303.62M | -401.93M | -214.64M | -119.36M | Investing Cash Flow |
0.00 | 468.20M | -645.59M | -2.04B | -113.07M | Financing Cash Flow |
0.00 | 72.13M | -8.06M | 3.64B | 7.40M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% | |
52 Neutral | HK$12.51B | ― | -18.87% | ― | 16.35% | -49.63% | |
$12.78B | 29.75 | 8.17% | ― | ― | ― | ||
59 Neutral | HK$3.76B | 21.09 | 4.47% | ― | -9.75% | ― | |
51 Neutral | HK$33.02B | ― | -56.68% | ― | 52.25% | 11.46% | |
50 Neutral | HK$73.83B | ― | -8.98% | ― | -54.66% | -123.11% | |
48 Neutral | HK$10.61B | ― | -4.41% | ― | 94.98% | 85.69% |
Keymed Biosciences Inc. has announced its upcoming Annual General Meeting scheduled for June 26, 2025, in Chengdu, China. The meeting will address several key resolutions, including the adoption of the 2024 financial statements, re-election of directors, and re-appointment of Ernst & Young as auditors. Additionally, the company seeks approval for the directors to issue new shares, which could impact its market position by potentially increasing capital for future projects.
Keymed Biosciences Inc. has announced a board meeting scheduled for March 24, 2025, to discuss and approve the company’s annual results for the year ending December 31, 2024, and to consider the payment of a final dividend. This meeting is significant as it will provide insights into the company’s financial performance and potential shareholder returns, impacting its market positioning and stakeholder interests.
Keymed Biosciences, Inc. announced that China’s National Medical Products Administration has approved the supplemental New Drug Application for Stapokibart, a humanized antibody, for the treatment of seasonal allergic rhinitis. This approval is based on a successful phase III study showing Stapokibart’s efficacy and safety in controlling nasal and ocular symptoms. This development marks Stapokibart as the first domestically manufactured IL-4R α antibody drug granted marketing approval, which could enhance Keymed’s positioning in the biopharmaceutical market.